This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Novartis (NVS) Commits to $5 Billion Share Repurchase

NEW YORK (TheStreet) -- Novartis (NVS - Get Report) has committed to returning $5 billion to shareholders through a two-year share repurchase program, a branch of its strategy to "strengthen portfolio and capital allocation." The pharmaceutical company will also accelerate growth through significant research and development and diversification into high-growth treatments such as those for skin and heart disease.

"Novartis has reached an inflection point, having fully integrated Alcon and reduced debt," said CEO Joseph Jimenez in a statement. The Basel-based business assumed majority control of ophthalmological company Alcon in 2011 after acquiring outstanding shares from Nestle.

"We are now further sharpening the execution of our strategy to strengthen shareholder value through science-based innovation in high-growth segments of healthcare where we have the global scale, competitive advantage and the right capabilities to win," continued Jimenez.

As part of its growth strategy, the company expects to realize 3% to 4% productivity gains per year through to 2015, by consolidating its global research sites and streamlining the manufacturing process.

Novartis also anticipates entering phase III trials for its potential gamechanger, the breast cancer pill LEE011, in December. Rival Pfizer (PFE) is currently undergoing phase III trials for its own pill, palbociclib.

By mid-morning, shares were 0.9% higher to $79.88, adding to 26.2% gains in the year to date.

--Written by Keris Alison Lahiff.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Submit an article to us!
SYM TRADE IT LAST %CHG
NVS $102.17 0.00%
AAPL $125.80 0.00%
FB $77.56 0.00%
GOOG $530.80 0.00%
TSLA $232.95 0.00%

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs